読み込み中
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
前日終値
$0.2148
−$0.0314 · -12.75%
時間外
$0.2234
+$0.0086 · +4.00%
10月12日 19:59 ET
日中の時刻はETです。市場データは遅延する場合があります。
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
日中レンジ
現在 $0.2148
52週レンジ
現在 $0.2148
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
強い売り
バリュエーション
7
著しい割高
センチメント
39
弱気
リスク
64
高リスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
日中レンジ
現在 $0.2148
52週レンジ
現在 $0.2148
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 19万 USD | 23.5万 USD | 35.3万 USD | 1038.6万 USD | — |
| 売上原価 | 155.3万 USD | — | — | 169.5万 USD | 130.4万 USD |
| 粗利益 | −136.3万 USD | 23.5万 USD | 35.3万 USD | 869.1万 USD | −130.4万 USD |
| 研究開発 | 6021.9万 USD | 5437.2万 USD | 4229.3万 USD | 4280.8万 USD | 2326.4万 USD |
| 販売・一般管理 | 1759.8万 USD | 1377.7万 USD | 1297.9万 USD | 1228.7万 USD | 1075.1万 USD |
| 営業費用 | 7626.4万 USD | 6814.9万 USD | 5527.2万 USD | 5509.5万 USD | 3271.1万 USD |
| 減価償却費と償却費 | 155.3万 USD | 154万 USD | 274.1万 USD | 169.5万 USD | 130.4万 USD |
| 営業利益 | −7762.7万 USD | −6791.4万 USD | −5491.9万 USD | −4640.4万 USD | −3401.5万 USD |
| 純利益 | −7411.8万 USD | −6402.3万 USD | −5038.9万 USD | −4533.8万 USD | −3376.8万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.13
上昇余地（2288.27%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年7月1日 | 1:14 | — | — |
発効済み 2019年7月1日
1:14
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
